Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Yongwei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9712-8964; OpenAlex author ID A5100664076. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: 4 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 24

  1. Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Format… Co-author DOI 10.1158/0008-5472.can-25-2854↗
  2. TCN1 Drives Malignant Progression of Pancreatic Cancer Through STAT4-Mediated Transcriptional Activation of the DUOX2/ROS Signaling Axis. Last author DOI 10.3390/cancers17203300↗
  3. Dual Starvations Induce Pyroptosis for Orthotopic Pancreatic Cancer Therapy through Simultaneous Deprivation of Glucose and Glutamine. Co-author DOI 10.1021/jacs.4c03478↗
  4. LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc. Co-author DOI 10.1093/carcin/bgad076↗
  5. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  6. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  7. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04693-4↗
  8. The Prognostic and Immune Significance of CILP2 in Pan-Cancer and Its Relationship with the Progression of Pancreatic Cancer. Last author DOI 10.3390/cancers15245842↗
  9. Beneficial Diets and Pancreatic Cancer: Molecular Mechanisms and Clinical Practice. Co-author DOI 10.3389/fonc.2021.630972↗
  10. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  11. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  12. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  13. Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis. Co-author DOI 10.1007/s10637-017-0508-2↗
  14. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Co-author DOI 10.1016/j.biomaterials.2017.12.015↗
  15. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0839-8↗
  16. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.05.015↗
  17. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. Co-author DOI 10.18632/oncotarget.18669↗
  18. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo. First author DOI 10.1007/s13277-015-4552-2↗
  19. Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy. Co-author DOI 10.1158/1535-7163.mct-16-0008↗
  20. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. First author DOI 10.18632/oncotarget.11517↗
  21. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.18632/oncotarget.12365↗
  22. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both… Co-author DOI 10.1007/s00432-012-1152-z↗
  23. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. Co-author DOI 10.1371/journal.pone.0037222↗
  24. Nuclear factor-κB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.1371/journal.pone.0023752↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bei Sun · 15 shared papers, 2011–2024 · strength 1.31
  2. Rui Kong · 15 shared papers, 2011–2026 · strength 1.28
  3. Jisheng Hu · 7 shared papers, 2017–2026 · strength 0.90
  4. Guanqun Li · 6 shared papers, 2018–2026 · strength 0.87
  5. Hongze Chen · 7 shared papers, 2016–2023 · strength 0.78
  6. Zonglin Liu · 3 shared papers, 2023–2025 · strength 0.74
  7. Bei Sun · 5 shared papers, 2019–2026 · strength 0.72
  8. Gang Wang · 6 shared papers, 2016–2026 · strength 0.72
  9. Danxi Liu · 4 shared papers, 2023–2024 · strength 0.72
  10. Shangha Pan · 10 shared papers, 2011–2023 · strength 0.65
  11. Yilong Li · 7 shared papers, 2016–2024 · strength 0.62
  12. Zhongjie Zhao · 5 shared papers, 2016–2023 · strength 0.60
  13. Le Li · 6 shared papers, 2016–2023 · strength 0.58
  14. Le Li · 4 shared papers, 2016–2026 · strength 0.57
  15. Wenbo Yang · 4 shared papers, 2021–2023 · strength 0.57
  16. Chundong Cheng · 3 shared papers, 2023–2024 · strength 0.54
  17. Xinglong Geng · 3 shared papers, 2021–2023 · strength 0.41
  18. Dongbo Xue · 3 shared papers, 2011–2025 · strength 0.39
  19. Yan Luo · 2 shared papers, 2023–2026 · strength 0.38
  20. Xuewei Bai · 5 shared papers, 2011–2023 · strength 0.37
  21. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  22. Tao Zhang · 2 shared papers, 2021–2023 · strength 0.27
  23. Le Li · 3 shared papers, 2017–2020 · strength 0.23
  24. Xinlong Wang · 1 shared paper, 2024 · strength 0.18
  25. Ping'an Ma · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.